Compare · DXCM vs RCEL
DXCM vs RCEL
Side-by-side comparison of DexCom Inc. (DXCM) and Avita Medical Inc. (RCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and RCEL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 230.9x RCEL ($128.0M).
- Over the past year, DXCM is down 10.6% and RCEL is down 31.8% - DXCM leads by 21.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 15 for RCEL).
- DXCM has more recent analyst coverage (25 ratings vs 7 for RCEL).
- Company
- DexCom Inc.
- Avita Medical Inc.
- Price
- $76.59+5.15%
- $4.21+0.24%
- Market cap
- $29.57B
- $128.0M
- 1M return
- +25.71%
- +0.96%
- 1Y return
- -10.56%
- -31.82%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 15
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Avita Medical Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest RCEL
- SEC Form 424B5 filed by Avita Medical Inc.
- Avita Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Woody Joseph Fralin bought $40,949 worth of shares (10,000 units at $4.09), increasing direct ownership by 12% to 92,761 units (SEC Form 4)
- Director Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)
- Director Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)
- Director Tarnoff Michael E was granted 48,464 shares (SEC Form 4)
- Director Cook Jeremy Curnock was granted 22,214 shares, increasing direct ownership by 56% to 62,050 units (SEC Form 4)
- Director Crowe Suzanne was granted 22,214 shares, increasing direct ownership by 47% to 69,148 units (SEC Form 4)
- Director Reed Jan Stern was granted 22,214 shares, increasing direct ownership by 44% to 73,225 units (SEC Form 4)
- Director Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)